Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031

Market Size
$67.95B
MARKET SIZE, 2026
Projected Market Size
$112.10B
MARKET SIZE, 2031
CAGR
10.5%
CAGR (2026-2031)
Forecast Period
2026-2031
FORECAST PERIOD

BIOMARKERS MARKET SIZE, SHARE & GROWTH SNAPSHOT

biomarkers-advanced-technologies-and-global-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, at a CAGR of 10.5% during the forecast period. The market was valued at USD 62.67 billion in 2025. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.

KEY TAKEAWAYS

  • MARKET SNAPSHOT:
    Current Market Size (2026): USD 67.95 Billion
    Projected Market Size (2031): USD 112.10 Billion
    CAGR (2026–2031): 10.5%
  • SEGMENT LEADERSHIP:
    Fastest-Growing Region: Asia Pacific is projected to register the highest CAGR of 12.4% during the forecast period.
    Offering Leader: Consumables segment held the largest share of 73.4% in 2025.
    Type Leader: Safety biomarkers segment dominated the global biomarkers market with a share of 48.5% in 2025.
    Research Area Leader: Genomics segment is expected to dominate the market during the forecast period.
  • MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
    F. Hoffmann-La Roche (Switzerland), Abbott (US), and Thermo Fisher Scientific (US) were identified as the star players in the global biomarkers market, given their strong market share and product footprint.
    DNAnexus, Inc. (US), Biocartis NV (Belgium), and Alamar Biosciences, Inc. (US) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The global biomarkers market is expanding rapidly, driven by the surge in precision-medicine programs and the routine use of biomarker-guided tests in oncology, cardiology, and other complex diseases.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The biomarkers market is experiencing rapid growth due to changes in manufacturing and regulatory environments that align with precision medicine and biologic therapies. The increasing demand for diagnoses in cancer, cardiovascular diseases, and neurological conditions is driving the adoption of high-performance assay kits, multiplexing platforms, and single-sample multi-omics solutions that deliver accurate and clinically relevant data. Hospitals, laboratory networks, and contract development and manufacturing organizations (CDMOs) are embracing validated, automation-friendly biomarker consumables and solutions that yield fast results, support companion diagnostics, and comply with strict FDA regulations.

biomarkers-advanced-technologies-and-global-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising adoption of precision medicine and companion diagnostics
  • Growing use of NGS, PCR, proteomics, and multi-omics platforms
RESTRAINTS
Impact
Level
  • High cost of advanced biomarker discovery and validation
  • Complex regulatory and reimbursement pathways
OPPORTUNITIES
Impact
Level
  • Co-development of biomarkers with targeted therapies and immunotherapies
  • Expansion of blood-based biomarkers for oncology and neurology
CHALLENGES
Impact
Level
  • Translating discovery biomarkers into clinically validated tests
  • Patient heterogeneity and disease complexity

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising adoption of precision medicine and companion diagnostics

The rising adoption of precision medicine and companion diagnostics is driving the demand for biomarker discovery and validation solutions. Advances in genomics, proteomics, metabolomics, and high-throughput screening technologies are improving the efficiency of biomarker identification, enhancing clinical validation capabilities, and supporting greater scalability in both research and clinical applications.

Restraint: High cost of advanced biomarker discovery and validation

The high costs associated with advanced analytical platforms, multi-omics technologies, clinical validation studies, and regulatory compliance continue to hinder the widespread adoption of biomarkers. Significant investments are needed in infrastructure, skilled expertise, and data integration capabilities, which present challenges, especially for smaller research organizations and emerging biotechnology companies.

Opportunity: Co-development of biomarkers with targeted therapies and immunotherapies

The increasing integration of biomarkers with targeted therapies and immunotherapies is creating opportunities for the collaborative development of drugs and diagnostics. There is a growing emphasis on patient stratification, treatment response prediction, and personalized treatment approaches. This focus is driving demand for companion diagnostic solutions and expanding their commercial potential in precision healthcare.

Challenges: Translating discovery biomarkers into clinically validated tests

Transforming biomarker discoveries from the research stage into clinically validated diagnostic tests is challenging for several reasons. These include complex validation requirements, regulatory expectations, concerns about reproducibility, and a lack of standardization across clinical settings. To achieve successful commercialization and adoption of these tests, it is essential to ensure analytical accuracy and demonstrate clinical utility.

BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
NGS-based comprehensive genomic profiling (CGP) and multi-omic biomarkers (including high-sensitive Troponin T, NT-proBNP) for cancer, cardiovascular, and neurology applications.  Supports personalized treatment plans, rapid rule-in/rule-out diagnostics from single tests, earlier detection, and companion diagnostics across oncology, cardiology, and neurology. 
High-sensitivity immunoassays and blood-based biomarkers for cancer, cardiovascular, and neurological diseases, including amyloid β testing for Alzheimer’s.  Enables non-invasive early diagnosis, risk stratification, and monitoring for chronic conditions like Alzheimer's, cancer, and CVD. 

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The biomarkers market is a complex ecosystem that includes assay developers, suppliers of kits and instruments, clinical laboratories, hospitals, and biopharmaceutical companies. Biomarker vendors provide validated assays and analytical platforms that pharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) incorporate into clinical trial designs, patient stratification, and therapeutic response assessments. Hospitals and reference laboratories then integrate these biomarker solutions into clinical practice, with support from healthcare IT vendors, distribution channels, and reimbursement systems that facilitate test adoption, optimize supply chains, and ensure reimbursement. This highly interconnected value chain enables the global implementation of biomarker-based precision medicine strategies within healthcare systems.

biomarkers-advanced-technologies-and-global-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

biomarkers-advanced-technologies-and-global-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Global Biomarkers Market, by Offering

In 2025, consumables accounted for the largest share of the biomarkers market, driven by the steady, high-volume demand for assay kits, reagents, plates, and cartridges in routine clinical diagnostics and extensive research programs.

Global Biomarkers Market, by Type

In 2025, safety biomarkers accounted for the largest share, fueled by their expanding role in real-time tracking of organ toxicity and adverse drug effects across clinical trials and post-approval monitoring.

Global Biomarkers Market, by Research Area

In 2025, genomics will be a leading research area due to the widespread adoption of next-generation sequencing and gene panels to identify treatment-relevant mutations and develop integrated biomarker profiles for oncology and rare disease initiatives.

Global Biomarkers Market, by Technology

In 2025, immunoassay technologies held the largest market share due to their automation-friendly nature and suitability for high-volume routine testing in hospitals and reference laboratories.

Global Biomarkers Market, by Disease Indication

In 2025, cancer dominated biomarker spending, as oncology programs rely heavily on molecular and protein markers for early detection, patient stratification, minimal residual disease tracking, and therapy monitoring.

Global Biomarkers Market, by Application

Clinical diagnostics accounted for the largest share of the biomarkers market, as hospitals and reference labs increasingly use biomarker-based tests for routine cancer, cardiovascular, and infectious disease workups.

Global Biomarkers Market, by End User

Pharmaceutical & biotechnology companies formed the largest end-user group by harnessing biomarkers to mitigate R&D risks, design efficient clinical trials, and secure regulatory approval for companion diagnostics tied to novel therapies.

REGION

APAC to be fastest-growing region in market during forecast period

During the forecast period, the Asia Pacific region is expected to experience the fastest growth in the global biomarkers market. This growth is attributed to the expansion of healthcare infrastructure, increased clinical trial activity, and robust government support for precision medicine initiatives, particularly in key countries such as China, India, and Japan.

biomarkers-advanced-technologies-and-global-market Region

BIOMARKERS MARKET: COMPANY EVALUATION MATRIX

In the global biomarkers market, F. Hoffmann-La Roche Ltd. (Switzerland) is the star player, offering an extensive portfolio of FDA-cleared and CE-marked assays, automated immunoassay platforms, and integrated diagnostic solutions trusted worldwide for high-throughput testing in oncology, cardiology, neurology, and infectious disease panels. Guardant Health (emerging leader) leverages advanced NGS liquid biopsy tests, comprehensive cancer panels, and AI-driven analytics to transform circulating tumor DNA biomarkers into actionable insights for early detection, therapy selection, and minimal residual disease monitoring across major healthcare systems globally.

biomarkers-advanced-technologies-and-global-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 62.47 Billion
Market Forecast in 2026 (Value) USD 67.95 Billion
Market Forecast in 2031 (Value) USD 112.10 Billion
Growth Rate CAGR of 10.5% from 2026–2031
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends
Segments Covered
  • By Offering:
    • Consumables
    • Service
    • software
  • By Type:
    • Safety Biomarkers
    • Efficacy Biomarkers
    • Validation Biomarkers
  • By Research Area:
    • Genomics
    • Proteomics
    • Metabolomics
    • Other Research Areas
  • By Technology:
    • Immunoassays
    • PCR
    • Mass Spectroscopy
    • NGS
    • Chromatography
    • Other Techniques
  • By Disease Indication:
    • Cancer
    • Infectious Diseases
    • Immunological Disorders
    • Neurological Disorders
    • Cardiovascular Disorders
    • Other Disease Indications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Hospitals & Diagnostic Laboratories
    • Academic & Research Institutes
    • Other End Users
Countries Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: BIOMARKERS MARKET REPORT CONTENT GUIDE

biomarkers-advanced-technologies-and-global-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Regulatory compliance for global markets Assessed regulatory requirements for biomarker assays across major markets, including FDA, EMA, and PMDA guidelines. Reduces time-to-market risk by ensuring assays meet local regulations and compliance standards.
Emerging biomarker trends and unmet needs Identified high-value biomarkers in oncology, immunology, and chronic diseases with limited commercial availability. Informs pipeline prioritization, partnership opportunities, and innovation roadmaps.

RECENT DEVELOPMENTS

  • June 2026 : Roche's first companion diagnostic to assess PTEN protein in prostate cancer has been approved by the FDA. The VENTANA PTEN assay allows for the identification of patients, leading to more targeted treatment decisions.
  • January 2025 : Thermo Fisher Scientific, Inc. has partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the largest biomarker-focused proteomics study in the world.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
56
2
EXECUTIVE SUMMARY
 
 
 
 
 
61
3
PREMIUM INSIGHTS
 
 
 
 
 
67
4
MARKET OVERVIEW
Precision medicine and AI integration drive biomarker market growth amid cost and regulatory challenges.
 
 
 
 
 
71
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
RISING ADOPTION OF PRECISION MEDICINE AND COMPANION DIAGNOSTICS
 
 
 
 
 
 
4.2.1.2
GROWING USE OF NGS, PCR, PROTEOMICS, AND MULTI-OMICS PLATFORMS
 
 
 
 
 
 
4.2.1.3
INCREASING BIOMARKER USE IN DRUG DISCOVERY AND CLINICAL TRIAL DESIGN
 
 
 
 
 
 
4.2.1.4
RISING BURDEN OF CANCER, CARDIOVASCULAR, NEUROLOGICAL, AND INFECTIOUS DISEASES
 
 
 
 
 
 
4.2.1.5
EXPANSION OF LIQUID BIOPSY AND MINIMALLY INVASIVE BIOMARKER TESTING
 
 
 
 
 
 
4.2.1.6
INCREASING INTEGRATION OF AI, DIGITAL PATHOLOGY, AND BIOINFORMATICS
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
HIGH COST OF ADVANCED BIOMARKER DISCOVERY AND VALIDATION
 
 
 
 
 
 
4.2.2.2
COMPLEX REGULATORY AND REIMBURSEMENT PATHWAYS
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
CO-DEVELOPMENT OF BIOMARKERS WITH TARGETED THERAPIES AND IMMUNOTHERAPIES
 
 
 
 
 
 
4.2.3.2
EXPANSION OF BLOOD-BASED BIOMARKERS FOR ONCOLOGY AND NEUROLOGY
 
 
 
 
 
 
4.2.3.3
GROWTH IN PROTEOMICS, SPATIAL BIOLOGY, AND MULTI-OMICS BIOMARKER DISCOVERY
 
 
 
 
 
 
4.2.3.4
RISING OUTSOURCING OF BIOMARKER ASSAY DEVELOPMENT AND VALIDATION
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
PATIENT HETEROGENEITY AND DISEASE COMPLEXITY
 
 
 
 
 
 
4.2.4.2
TRANSLATING DISCOVERY BIOMARKERS INTO CLINICALLY VALIDATED TESTS
 
 
 
 
4.3
UNMET NEEDS & WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate industry shifts with strategic insights from competitive forces and global market dynamics.
 
 
 
 
 
80
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS & FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL BIOMARKERS MARKET
 
 
 
 
 
5.3
SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.5
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.6
PRICING ANALYSIS
 
 
 
 
 
 
 
 
 
AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER,
 
 
 
 
 
 
5.6.2
INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
 
 
 
 
 
5.7
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.7.1
IMPORT DATA
 
 
 
 
 
 
5.7.2
EXPORT DATA
 
 
 
 
 
 
5.7.3
IMPORT VOLUME
 
 
 
 
 
 
5.7.4
EXPORT VOLUME
 
 
 
 
 
5.8
KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.10
INVESTMENT/FUNDING ACTIVITY
 
 
 
 
 
 
5.11
CASE STUDY ANALYSIS
 
 
 
 
 
 
5.12
IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET
 
 
 
 
 
 
 
 
5.12.1
INTRODUCTION
 
 
 
 
 
 
5.12.2
KEY TARIFF RATES
 
 
 
 
 
 
5.12.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.12.4
IMPACT ON COUNTRY/REGION
 
 
 
 
 
 
 
5.12.4.1
NORTH AMERICA
 
 
 
 
 
 
5.12.4.2
EUROPE
 
 
 
 
 
 
5.12.4.3
ASIA PACIFIC
 
 
 
 
 
5.12.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.12.5.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.12.5.2
HOSPITALS & DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
5.12.5.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
5.12.5.4
OTHER END USERS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations redefine biomarker technologies, unlocking new market potentials and transformative applications.
 
 
 
 
 
102
 
6.1
TECHNOLOGY ANALYSIS
 
 
 
 
 
 
 
6.1.1
KEY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1.1
IMMUNOASSAYS
 
 
 
 
 
 
6.1.1.2
NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
 
 
6.1.1.3
POLYMERASE CHAIN REACTION (PCR)
 
 
 
 
 
 
6.1.1.4
IN SITU HYBRIDIZATION
 
 
 
 
 
 
6.1.1.5
MICROARRAYS
 
 
 
 
 
 
6.1.1.6
MASS SPECTROMETRY
 
 
 
 
 
6.1.2
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.1.2.1
ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML)
 
 
 
 
 
 
6.1.2.2
SENSORS (WEARABLE DEVICES)
 
 
 
 
 
6.1.3
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.3.1
LIQUID BIOPSY
 
 
 
 
 
 
6.1.3.2
CRISPR
 
 
 
 
6.2
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.3
PATENT ANALYSIS
 
 
 
 
 
 
 
 
 
TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS,
 
 
 
 
 
6.4
FUTURE APPLICATIONS
 
 
 
 
 
 
6.5
IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
 
 
 
 
 
 
 
 
6.5.1
TOP USE CASES & MARKET POTENTIAL
 
 
 
 
 
 
6.5.2
CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
 
 
 
 
 
 
6.5.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.5.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
 
 
 
 
 
6.6
SUCCESS STORIES & REAL-WORLD APPLICATIONS
 
 
 
 
 
7
SUSTAINABILITY & REGULATORY LANDSCAPE
Navigate complex global regulations to leverage sustainability initiatives and secure eco-certifications.
 
 
 
 
 
113
 
7.1
REGIONAL REGULATIONS & COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
REGULATORY FRAMEWORK
 
 
 
 
 
 
7.1.3
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
 
 
 
 
 
 
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand buyer dynamics to unlock unmet needs and navigate complex decision-making processes.
 
 
 
 
 
125
 
8.1
DECISION-MAKING PROCESS
 
 
 
 
 
 
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
 
 
 
 
 
 
 
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
 
 
8.2.2
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
 
 
 
 
 
 
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
 
 
 
 
 
 
8.5
MARKET PROFITABILITY
 
 
 
 
 
9
BIOMARKERS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 44 Data Tables
 
 
 
 
 
130
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
CONSUMABLES
 
 
 
 
 
 
 
9.2.1
ASSAY KITS
 
 
 
 
 
 
 
9.2.1.1
GROWING DEMAND FOR ASSAY KITS IN BIOMARKER DETECTION, QUANTIFICATION, AND CHARACTERIZATION TO SUPPORT GROWTH
 
 
 
 
 
9.2.2
REAGENTS & CHEMICALS
 
 
 
 
 
 
 
9.2.2.1
RECURRENT USAGE OF REAGENTS & CHEMICALS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT DEMAND
 
 
 
 
 
9.2.3
OTHER CONSUMABLES
 
 
 
 
 
9.3
SERVICES
 
 
 
 
 
 
 
9.3.1
GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
 
 
 
 
 
9.4
SOFTWARE
 
 
 
 
 
 
 
 
INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO
 
 
 
 
10
BIOMARKERS MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 51 Data Tables
 
 
 
 
 
156
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
SAFETY BIOMARKERS
 
 
 
 
 
 
 
10.2.1
WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS & DEVELOPMENT TO BOOST MARKET GROWTH
 
 
 
 
 
10.3
EFFICACY BIOMARKERS
 
 
 
 
 
 
 
10.3.1
PREDICTIVE BIOMARKERS
 
 
 
 
 
 
 
10.3.1.1
RISING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE TO DRIVE MARKET
 
 
 
 
 
10.3.2
SURROGATE BIOMARKERS
 
 
 
 
 
 
 
10.3.2.1
ABILITY TO SERVE AS RELIABLE INDICATORS IN PLACE OF CLINICAL ENDPOINTS TO SUPPORT MARKET GROWTH
 
 
 
 
 
10.3.3
PHARMACODYNAMIC BIOMARKERS
 
 
 
 
 
 
 
10.3.3.1
INCREASING UTILIZATION OF PHARMACODYNAMIC BIOMARKERS IN BIOMARKER AND DRUG DEVELOPMENT TO BOOST MARKET
 
 
 
 
 
10.3.4
PROGNOSTIC BIOMARKERS
 
 
 
 
 
 
 
10.3.4.1
INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT GROWTH OF PROGNOSTIC BIOMARKERS
 
 
 
 
10.4
VALIDATION BIOMARKERS
 
 
 
 
 
 
 
10.4.1
RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH
 
 
 
 
11
BIOMARKERS MARKET, BY RESEARCH AREA
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
185
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
GENOMICS
 
 
 
 
 
 
 
11.2.1
ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
 
 
 
 
 
11.3
PROTEOMICS
 
 
 
 
 
 
 
11.3.1
GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
 
 
 
 
 
11.4
METABOLOMICS
 
 
 
 
 
 
 
11.4.1
RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
 
 
 
 
 
11.5
OTHER RESEARCH AREAS
 
 
 
 
 
12
BIOMARKERS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 65 Data Tables
 
 
 
 
 
203
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
IMMUNOASSAYS
 
 
 
 
 
 
 
12.2.1
ELISA
 
 
 
 
 
 
 
12.2.1.1
EXTENSIVE APPLICATION OF ELISA ASSAYS IN CLINICAL LABORATORIES TO SUPPORT GROWTH
 
 
 
 
 
12.2.2
PROTEIN MICROARRAYS
 
 
 
 
 
 
 
12.2.2.1
QUICK AND COST-EFFECTIVE NATURE OF TECHNOLOGY TO SUPPORT GROWTH
 
 
 
 
 
12.2.3
WESTERN BLOT
 
 
 
 
 
 
 
12.2.3.1
INCREASING INVESTMENTS IN PROTEOMICS RESEARCH TO DRIVE MARKET
 
 
 
 
12.3
NEXT-GENERATION SEQUENCING (NGS)
 
 
 
 
 
 
 
12.3.1
TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
 
 
 
 
 
12.4
POLYMERASE CHAIN REACTION (PCR)
 
 
 
 
 
 
 
12.4.1
RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
 
 
 
 
 
12.5
MASS SPECTROMETRY
 
 
 
 
 
 
 
12.5.1
INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH
 
 
 
 
 
12.6
CHROMATOGRAPHY
 
 
 
 
 
 
 
12.6.1
GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
 
 
 
 
 
12.7
OTHER TECHNOLOGIES
 
 
 
 
 
13
BIOMARKERS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 38 Data Tables
 
 
 
 
 
240
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
CLINICAL DIAGNOSTICS
 
 
 
 
 
 
 
13.2.1
GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
 
 
 
 
 
13.3
DRUG DISCOVERY & DEVELOPMENT
 
 
 
 
 
 
 
13.3.1
INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
 
 
 
 
 
13.4
PERSONALIZED MEDICINE
 
 
 
 
 
 
 
13.4.1
GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
 
 
 
 
 
13.5
CLINICAL RESEARCH
 
 
 
 
 
 
 
13.5.1
GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
 
 
 
 
 
13.6
OTHER APPLICATIONS
 
 
 
 
 
14
BIOMARKERS MARKET, BY DISEASE INDICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 199 Data Tables
 
 
 
 
 
262
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
CANCER
 
 
 
 
 
 
 
14.2.1
BREAST CANCER
 
 
 
 
 
 
 
14.2.1.1
EXPANDING PRECISION ONCOLOGY AND COMPANION DIAGNOSTICS TO DRIVE GLOBAL GROWTH IN BREAST CANCER BIOMARKERS
 
 
 
 
 
14.2.2
LUNG CANCER
 
 
 
 
 
 
 
14.2.2.1
EXPANDING TARGETED THERAPIES AND RAPID MOLECULAR PROFILING TO DRIVE GLOBAL GROWTH IN LUNG CANCER BIOMARKERS
 
 
 
 
 
14.2.3
COLORECTAL CANCER
 
 
 
 
 
 
 
14.2.3.1
EXPANDING RAS/BRAF TESTING, LIQUID BIOPSY, AND BIOMARKER-LINKED TARGETED THERAPIES TO DRIVE GLOBAL
 
 
 
 
 
14.2.4
PROSTATE CANCER
 
 
 
 
 
 
 
14.2.4.1
GROWTH IN HRR, PTEN, AND LIQUID BIOPSY TESTING TO ACCELERATE BIOMARKER ADOPTION
 
 
 
 
 
14.2.5
HEMATOLOGICAL CANCER
 
 
 
 
 
 
 
14.2.5.1
RISING MRD MONITORING AND TARGETED HEMATOLOGY THERAPIES TO DRIVE GLOBAL GROWTH IN HEMATOLOGICAL CANCER BIOMARKERS
 
 
 
 
 
14.2.6
OTHER CANCERS
 
 
 
 
 
14.3
INFECTIOUS DISEASES
 
 
 
 
 
 
 
14.3.1
HIV/AIDS
 
 
 
 
 
 
 
14.3.1.1
EXPANDING SELF-TESTING AND VIRAL LOAD MONITORING TO DRIVE GLOBAL GROWTH
 
 
 
 
 
14.3.2
HEPATITIS (B & C)
 
 
 
 
 
 
 
14.3.2.1
RISING HEPATITIS SCREENING AND AUTOMATED IMMUNOASSAY ADOPTION TO DRIVE GROWTH OF HBV AND HCV BIOMARKERS
 
 
 
 
 
14.3.3
RESPIRATORY INFECTIONS
 
 
 
 
 
 
 
14.3.3.1
RISING MRD MONITORING AND TARGETED HEMATOLOGY THERAPIES TO DRIVE GLOBAL GROWTH IN HEMATOLOGICAL CANCER BIOMARKERS
 
 
 
 
 
14.3.4
OTHER INFECTIOUS DISEASES
 
 
 
 
 
14.4
IMMUNOLOGICAL DISORDERS
 
 
 
 
 
 
 
14.4.1
RHEUMATOID ARTHRITIS
 
 
 
 
 
 
 
14.4.1.1
EARLIER DIAGNOSIS AND THERAPY-RESPONSE STRATIFICATION TO DRIVE GROWTH IN RHEUMATOID ARTHRITIS BIOMARKERS
 
 
 
 
 
14.4.2
INFLAMMATORY BOWEL DISEASE
 
 
 
 
 
 
 
14.4.2.1
NON-INVASIVE INFLAMMATION MONITORING AND TARGETED THERAPY MANAGEMENT TO DRIVE GROWTH IN IBD BIOMARKERS
 
 
 
 
 
14.4.3
OTHER IMMUNOLOGICAL DISORDERS
 
 
 
 
 
14.5
NEUROLOGICAL DISORDERS
 
 
 
 
 
 
 
14.5.1
ALZHEIMER’S DISEASE
 
 
 
 
 
 
 
14.5.1.1
GROWING DEMAND FOR LESS-INVASIVE ALTERNATIVES TO PET IMAGING AND CEREBROSPINAL FLUID TESTING TO BOOST MARKET GROWTH
 
 
 
 
 
14.5.2
PARKINSON’S DISEASE
 
 
 
 
 
 
 
14.5.2.1
ALPHA-SYNUCLEIN AND DIGITAL BIOMARKER ADVANCES TO DRIVE GROWTH IN PARKINSON’S DISEASE BIOMARKERS
 
 
 
 
 
14.5.3
MULTIPLE SCLEROSIS
 
 
 
 
 
 
 
14.5.3.1
BLOOD-BASED NEUROFILAMENT LIGHT CHAIN TESTING TO STRENGTHEN GROWTH IN MULTIPLE SCLEROSIS BIOMARKERS
 
 
 
 
 
14.5.4
OTHER NEUROLOGICAL DISORDERS
 
 
 
 
 
14.6
METABOLIC & ENDOCRINE DISORDERS
 
 
 
 
 
 
 
14.6.1
DIABETES
 
 
 
 
 
 
 
14.6.1.1
CONTINUOUS GLUCOSE-KETONE MONITORING AND CONNECTED DIABETES CARE TO DRIVE GROWTH IN DIABETES BIOMARKERS
 
 
 
 
 
14.6.2
OBESITY
 
 
 
 
 
 
 
14.6.2.1
GLP-1 THERAPY EXPANSION AND PAYER DEMAND FOR RESPONSE PREDICTION TO DRIVE GROWTH IN OBESITY BIOMARKERS
 
 
 
 
 
14.6.3
OTHER METABOLIC & ENDOCRINE DISORDERS
 
 
 
 
 
14.7
CARDIOVASCULAR DISORDERS
 
 
 
 
 
 
 
14.7.1
CONTINUOUS INNOVATION IN CARDIAC BIOMARKERS TO BOOST MARKET GROWTH
 
 
 
 
 
14.8
OTHER DISEASE INDICATIONS
 
 
 
 
 
15
BIOMARKERS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
364
 
15.1
INTRODUCTION
 
 
 
 
 
 
15.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
15.2.1
GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH
 
 
 
 
 
15.3
HOSPITALS & DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
 
15.3.1
VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
 
 
 
 
 
15.4
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
15.4.1
INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
 
 
 
 
 
15.5
OTHER END USERS
 
 
 
 
 
16
BIOMARKERS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 427 Data Tables.
 
 
 
 
 
381
 
16.1
INTRODUCTION
 
 
 
 
 
 
16.2
NORTH AMERICA
 
 
 
 
 
 
 
16.2.1
US
 
 
 
 
 
 
 
16.2.1.1
RISING FOCUS ON BIOPHARMA RESEARCH TO SUPPORT GROWTH
 
 
 
 
 
16.2.2
CANADA
 
 
 
 
 
 
 
16.2.2.1
INCREASING INCIDENCE OF CANCER TO DRIVE BIOMARKERS MARKET GROWTH
 
 
 
 
16.3
EUROPE
 
 
 
 
 
 
 
16.3.1
GERMANY
 
 
 
 
 
 
 
16.3.1.1
GROWTH IN BIOPHARMACEUTICAL R&D ACTIVITIES TO PROPEL GROWTH
 
 
 
 
 
16.3.2
UK
 
 
 
 
 
 
 
16.3.2.1
GOVERNMENT FUNDING AND STRATEGIC COLLABORATIONS WITH BIOTECH FIRMS TO BOOST ADOPTION OF BIOMARKERS
 
 
 
 
 
16.3.3
FRANCE
 
 
 
 
 
 
 
16.3.3.1
INCREASING GOVERNMENT INVESTMENT FOR PROTEOMICS & GENOMICS RESEARCH TO DRIVE GROWTH
 
 
 
 
 
16.3.4
ITALY
 
 
 
 
 
 
 
16.3.4.1
INCREASING DEVELOPMENTS IN LIFE SCIENCE RESEARCH TO FUEL GROWTH
 
 
 
 
 
16.3.5
SPAIN
 
 
 
 
 
 
 
16.3.5.1
R&D INITIATIVES FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
 
 
 
 
 
16.3.6
REST OF EUROPE
 
 
 
 
 
16.4
ASIA PACIFIC
 
 
 
 
 
 
 
16.4.1
CHINA
 
 
 
 
 
 
 
16.4.1.1
RISING INCIDENCE OF CVD TO PROPEL MARKET
 
 
 
 
 
16.4.2
JAPAN
 
 
 
 
 
 
 
16.4.2.1
STRONG REGULATORY GUIDELINES FOR DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
 
 
 
 
 
16.4.3
INDIA
 
 
 
 
 
 
 
16.4.3.1
FAVORABLE SCENARIO FOR FDI AND INCREASING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
 
 
 
 
 
16.4.4
SOUTH KOREA
 
 
 
 
 
 
 
16.4.4.1
INCREASING INNOVATIONS IN NGS TECHNOLOGIES TO SUPPORT MARKET GROWTH
 
 
 
 
 
16.4.5
AUSTRALIA
 
 
 
 
 
 
 
16.4.5.1
INCREASING DEMAND FOR DIAGNOSTIC SOLUTIONS TO PROPEL MARKET
 
 
 
 
 
16.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
16.5
LATIN AMERICA
 
 
 
 
 
 
 
16.5.1
BRAZIL
 
 
 
 
 
 
 
16.5.1.1
INCREASED GOVERNMENT INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
 
 
 
 
 
16.5.2
MEXICO
 
 
 
 
 
 
 
16.5.2.1
RISING DEMAND FOR CHRONIC DISEASE TREATMENT TO SUPPORT MARKET GROWTH
 
 
 
 
 
16.5.3
REST OF LATIN AMERICA
 
 
 
 
 
16.6
MIDDLE EAST
 
 
 
 
 
 
 
16.6.1
GCC COUNTRIES
 
 
 
 
 
 
 
16.6.1.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
16.6.1.1.1
GROWING HEALTHCARE EXPENDITURE TO BOOST MARKET GROWTH
 
 
 
 
16.6.1.2
UAE
 
 
 
 
 
 
 
 
16.6.1.2.1
INCREASING COLLABORATIVE EFFORTS FOR PHARMACEUTICAL R&D TO DRIVE GROWTH
 
 
 
 
16.6.1.3
REST OF GCC COUNTRIES
 
 
 
 
 
16.6.2
REST OF MIDDLE EAST
 
 
 
 
 
16.7
AFRICA
 
 
 
 
 
 
 
16.7.1
INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET
 
 
 
 
17
COMPETITIVE LANDSCAPE
Discover strategic shifts and key players shaping the biomarkers market's competitive edge.
 
 
 
 
 
589
 
17.1
OVERVIEW
 
 
 
 
 
 
17.2
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023−2026
 
 
 
 
 
 
17.3
REVENUE ANALYSIS, 2023–2025
 
 
 
 
 
 
 
17.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
17.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
17.5.1
STARS
 
 
 
 
 
 
17.5.2
EMERGING LEADERS
 
 
 
 
 
 
17.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
17.5.4
PARTICIPANTS
 
 
 
 
 
 
17.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
17.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
17.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
17.5.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
17.5.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
17.5.5.5
APPLICATION FOOTPRINT
 
 
 
 
17.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
17.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
17.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
17.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
17.6.4
STARTING BLOCKS
 
 
 
 
 
 
17.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
17.6.5.1
DETAILED LIST OF KEY STARTUPS/SME PLAYERS
 
 
 
 
 
 
17.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS
 
 
 
 
17.7
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
 
 
17.7.1
FINANCIAL METRICS
 
 
 
 
 
 
17.7.2
COMPANY VALUATION
 
 
 
 
 
17.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
17.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
17.9.1
PRODUCT LAUNCHES & APPROVALS
 
 
 
 
 
 
17.9.2
DEALS
 
 
 
 
 
 
17.9.3
EXPANSIONS
 
 
 
 
18
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
611
 
18.1
KEY PLAYERS
 
 
 
 
 
 
 
18.1.1
F. HOFFMANN-LA ROCHE LTD.
 
 
 
 
 
 
 
18.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
18.1.1.2
PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
18.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
18.1.1.3.1
PRODUCT LAUNCHES & APPROVALS
 
 
 
 
 
 
18.1.1.3.2
DEALS
 
 
 
 
18.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
18.1.1.4.1
RIGHT TO WIN
 
 
 
 
 
 
18.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
18.1.1.4.3
WEAKNESSES & COMPETITIVE THREATS
 
 
 
18.1.2
DANAHER CORPORATION
 
 
 
 
 
 
18.1.3
ILLUMINA, INC.
 
 
 
 
 
 
18.1.4
MERCK KGAA
 
 
 
 
 
 
18.1.5
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
18.1.6
QIAGEN
 
 
 
 
 
 
18.1.7
ABBOTT
 
 
 
 
 
 
18.1.8
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
18.1.9
REVVITY INC.
 
 
 
 
 
 
18.1.10
CHARLES RIVER LABORATORIES
 
 
 
 
 
 
18.1.11
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
18.1.12
EUROFINS SCIENTIFIC
 
 
 
 
 
 
18.1.13
BIOMÉRIEUX
 
 
 
 
 
 
18.1.14
JSR CORPORATION
 
 
 
 
 
 
18.1.15
GUARDANT HEALTH
 
 
 
 
 
 
18.1.16
LABCORP
 
 
 
 
 
 
18.1.17
QUANTERIX
 
 
 
 
 
 
18.1.18
MESO SCALE DIAGNOSTICS, LLC
 
 
 
 
 
 
18.1.19
SIEMENS HEALTHINEERS AG
 
 
 
 
 
18.2
OTHER PLAYERS
 
 
 
 
 
 
 
18.2.1
CELERION
 
 
 
 
 
 
18.2.2
STANDARD BIOTOOLS
 
 
 
 
 
 
18.2.3
SEBIA
 
 
 
 
 
 
18.2.4
BIOAGILYTIX LABS
 
 
 
 
 
 
18.2.5
STRESSMARQ BIOSCIENCES INC.
 
 
 
 
 
 
18.2.6
NORTHEAST BIOANALYTICAL LABORATORIES LLC
 
 
 
 
 
 
18.2.7
SIGNOSIS
 
 
 
 
 
 
18.2.8
SERIMMUNE
 
 
 
 
 
 
18.2.9
THERAINDX LIFESCIENCES PVT. LTD.
 
 
 
 
 
 
18.2.10
SYNEXA LIFE SCIENCES BV
 
 
 
 
 
 
18.2.11
DIATECH PHARMACOGENETICS
 
 
 
 
 
 
18.2.12
PILLAR BIOSCIENCES
 
 
 
 
 
 
18.2.13
R-BIOPHARM AG
 
 
 
 
19
RESEARCH METHODOLOGY
 
 
 
 
 
708
 
19.1
RESEARCH DATA
 
 
 
 
 
 
 
19.1.1
SECONDARY DATA
 
 
 
 
 
 
19.1.2
PRIMARY DATA
 
 
 
 
 
19.2
MARKET ESTIMATION METHODOLOGY
 
 
 
 
 
 
 
19.2.1
INSIGHTS OF PRIMARY EXPERTS
 
 
 
 
 
 
19.2.2
TOP-DOWN APPROACH
 
 
 
 
 
19.3
MARKET GROWTH RATE FORECAST
 
 
 
 
 
 
19.4
MARKET BREAKDOWN & DATA TRIANGULATION
 
 
 
 
 
 
19.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
19.6
RESEARCH LIMITATIONS
 
 
 
 
 
 
19.7
RISK ASSESSMENT
 
 
 
 
 
20
APPENDIX
 
 
 
 
 
721
 
20.1
DISCUSSION GUIDE
 
 
 
 
 
 
20.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
20.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
20.4
RELATED REPORTS
 
 
 
 
 
 
20.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
BIOMARKERS MARKET: IMPACT ANALYSIS
 
 
 
 
 
 
TABLE 2
BIOMARKERS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 3
BIOMARKERS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 4
AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 5
INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
 
 
 
 
 
 
TABLE 6
IMPORT DATA FOR HS CODE 382219, 2022–2025, (USD THOUSAND)
 
 
 
 
 
 
TABLE 7
EXPORT DATA HS CODE 382200, 2022–2025, (USD THOUSAND)
 
 
 
 
 
 
TABLE 8
IMPORT VOLUME HS CODE 382219, 2022–2025 (TONS)
 
 
 
 
 
 
TABLE 9
EXPORT VOLUME HS CODE 382219, 2022–2025 (TONS)
 
 
 
 
 
 
TABLE 10
BIOMARKERS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 11
CASE STUDY 1: ADVANCED GENOMIC PROFILING TO SUPPORT PRECISION ONCOLOGY ADOPTION
 
 
 
 
 
 
TABLE 12
CASE STUDY 2: EXPANSION OF LIQUID BIOPSY ACCESS FOR MINIMALLY INVASIVE CANCER BIOMARKER TESTING
 
 
 
 
 
 
TABLE 13
CASE STUDY 3: POPULATION PROTEOMICS EXPANSION TO ACCELERATE BIOMARKER DISCOVERY
 
 
 
 
 
 
TABLE 14
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 15
INDICATIVE LIST OF PATENTS IN BIOMARKERS MARKET, 2025
 
 
 
 
 
 
TABLE 16
CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
 
 
 
 
 
 
TABLE 17
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
 
 
 
 
 
 
TABLE 18
KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATIONS IN BIOMARKERS MARKET
 
 
 
 
 
 
TABLE 19
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 22
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 23
COUNTRY-WISE REGULATORY SCENARIO FOR BIOMARKER-BASED PRODUCT & SERVICE PROVIDERS
 
 
 
 
 
 
TABLE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%)
 
 
 
 
 
 
TABLE 25
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
TABLE 26
BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
BIOMARKER ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
NORTH AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
EUROPE: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
ASIA PACIFIC: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
LATIN AMERICA: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
MIDDLE EAST: BIOMARKER ASSAY KITS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
GCC COUNTRIES: BIOMARKER ASSAY KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
NORTH AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
EUROPE: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
ASIA PACIFIC: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
LATIN AMERICA: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
MIDDLE EAST: BIOMARKER REAGENTS & CHEMICALS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
GCC COUNTRIES: BIOMARKER REAGENTS & CHEMICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
NORTH AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
EUROPE: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
ASIA PACIFIC: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
LATIN AMERICA: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
MIDDLE EAST: OTHER BIOMARKER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
GCC COUNTRIES: OTHER BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
BIOMARKER SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
LATIN AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
MIDDLE EAST: BIOMARKER SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
GCC COUNTRIES: BIOMARKER SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
BIOMARKER SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
LATIN AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
MIDDLE EAST: BIOMARKER SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
GCC COUNTRIES: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
SAFETY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
LATIN AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
MIDDLE EAST: SAFETY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
GCC COUNTRIES: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
EFFICACY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
LATIN AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
MIDDLE EAST: PREDICTIVE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
GCC COUNTRIES: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
SURROGATE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
LATIN AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
MIDDLE EAST: SURROGATE BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
GCC COUNTRIES: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
LATIN AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
MIDDLE EAST: PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
GCC COUNTRIES: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
LATIN AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
MIDDLE EAST: PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
GCC COUNTRIES: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
VALIDATION BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
LATIN AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
MIDDLE EAST: VALIDATION BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
GCC COUNTRIES: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
NORTH AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
EUROPE: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
ASIA PACIFIC: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
LATIN AMERICA: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
MIDDLE EAST: BIOMARKERS MARKET FOR GENOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
GCC COUNTRIES: BIOMARKERS MARKET FOR GENOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
NORTH AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
EUROPE: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
LATIN AMERICA: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
MIDDLE EAST: BIOMARKERS MARKET FOR PROTEOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
NORTH AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
EUROPE: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
LATIN AMERICA: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
MIDDLE EAST: BIOMARKERS MARKET FOR METABOLOMICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLOMICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
EUROPE: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 151
BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 152
NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 153
EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 154
ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 155
LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 156
MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 157
GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 158
BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 159
BIOMARKERS MARKET FOR ELISA, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 160
NORTH AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 161
EUROPE: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 162
ASIA PACIFIC: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 163
LATIN AMERICA: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 164
MIDDLE EAST: BIOMARKERS MARKET FOR ELISA, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 165
GCC COUNTRIES: BIOMARKERS MARKET FOR ELISA, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 166
BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 167
NORTH AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 168
EUROPE: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 169
ASIA PACIFIC: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 170
LATIN AMERICA: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 171
MIDDLE EAST: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 172
GCC COUNTRIES: BIOMARKERS MARKET FOR PROTEIN MICROARRAYS, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 173
BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 174
NORTH AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 175
EUROPE: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 176
ASIA PACIFIC: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 177
LATIN AMERICA: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 178
MIDDLE EAST: BIOMARKERS MARKET FOR WESTERN BLOT, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 179
GCC COUNTRIES: BIOMARKERS MARKET FOR WESTERN BLOT, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 180
BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 181
NORTH AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 182
EUROPE: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 183
ASIA PACIFIC: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 184
LATIN AMERICA: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 185
MIDDLE EAST: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 186
GCC COUNTRIES: BIOMARKERS MARKET FOR NEXT-GENERATION SEQUENCING, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 187
BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 188
NORTH AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 189
EUROPE: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 190
ASIA PACIFIC: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 191
LATIN AMERICA: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 192
MIDDLE EAST: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 193
GCC COUNTRIES: BIOMARKERS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 194
BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 195
NORTH AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 196
EUROPE: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 197
ASIA PACIFIC: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 198
LATIN AMERICA: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 199
MIDDLE EAST: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 200
GCC COUNTRIES: BIOMARKERS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 201
BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 202
NORTH AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 203
EUROPE: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 204
ASIA PACIFIC: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 205
LATIN AMERICA: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 206
MIDDLE EAST: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 207
GCC COUNTRIES: BIOMARKERS MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 208
BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 209
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 210
EUROPE: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 211
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 212
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 213
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 214
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031(USD MILLION)
 
 
 
 
 
 
TABLE 215
BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
EUROPE: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
LATIN AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
MIDDLE EAST: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
GCC COUNTRIES: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
LIST OF KEY PERSONALIZED MEDICINE AND RELEVANT BIOMARKERS
 
 
 
 
 
 
TABLE 231
BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
LATIN AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
MIDDLE EAST: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
GCC COUNTRIES: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION
 
 
 
 
 
 
TABLE 239
BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
NORTH AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
EUROPE: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
ASIA PACIFIC: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
LATIN AMERICA: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
MIDDLE EAST: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
GCC COUNTRIES: BIOMARKERS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
LIST OF FDA-APPROVED BIOMARKERS FOR CANCER, BY TYPE
 
 
 
 
 
 
TABLE 255
BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
BIOMARKERS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
NORTH AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
EUROPE: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
ASIA PACIFIC: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
LATIN AMERICA: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
MIDDLE EAST: BIOMARKERS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
GCC COUNTRIES: BIOMARKERS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
NORTH AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
EUROPE: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
ASIA PACIFIC: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
LATIN AMERICA: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
MIDDLE EAST: BIOMARKERS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
GCC COUNTRIES: BIOMARKERS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
NORTH AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
EUROPE: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
ASIA PACIFIC: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
LATIN AMERICA: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
MIDDLE EAST: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
GCC COUNTRIES: BIOMARKERS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
NORTH AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
EUROPE: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
ASIA PACIFIC: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
LATIN AMERICA: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
MIDDLE EAST: BIOMARKERS MARKET FOR PROSTATE CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
GCC COUNTRIES: BIOMARKERS MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
NORTH AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
EUROPE: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
ASIA PACIFIC: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
LATIN AMERICA: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
MIDDLE EAST: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
GCC COUNTRIES: BIOMARKERS MARKET FOR HEMATOLOGICAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
EUROPE: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
NORTH AMERICA: INFECTIOUS DISEASES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
NORTH AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
EUROPE: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
ASIA PACIFIC: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
LATIN AMERICA: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
MIDDLE EAST: BIOMARKERS MARKET FOR HIV/AIDS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
GCC COUNTRIES: BIOMARKERS MARKET FOR HIV/AIDS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
NORTH AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
EUROPE: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
ASIA PACIFIC: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
LATIN AMERICA: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
MIDDLE EAST: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
GCC COUNTRIES: BIOMARKERS MARKET FOR HEPATITIS (B & C), BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
NORTH AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
EUROPE: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
ASIA PACIFIC: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
LATIN AMERICA: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
MIDDLE EAST: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
GCC COUNTRIES: BIOMARKERS MARKET FOR RESPIRATORY INFECTIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
EUROPE: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
 
 
 
 
 
 
TABLE 342
BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
NORTH AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
EUROPE: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
ASIA PACIFIC: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
LATIN AMERICA: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
MIDDLE EAST: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
GCC COUNTRIES: BIOMARKERS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
NORTH AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
EUROPE: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
ASIA PACIFIC: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
LATIN AMERICA: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
MIDDLE EAST: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
GCC COUNTRIES: BIOMARKERS MARKET FOR INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
EUROPE: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
NORTH AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
EUROPE: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
ASIA PACIFIC: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
LATIN AMERICA: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
MIDDLE EAST: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
GCC COUNTRIES: BIOMARKERS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
NORTH AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
EUROPE: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
ASIA PACIFIC: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
LATIN AMERICA: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
MIDDLE EAST: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
GCC COUNTRIES: BIOMARKERS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
NORTH AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
EUROPE: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
ASIA PACIFIC: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
LATIN AMERICA: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
MIDDLE EAST: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
GCC COUNTRIES: BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
EUROPE: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
NORTH AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
EUROPE: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
ASIA PACIFIC: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
LATIN AMERICA: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
MIDDLE EAST: BIOMARKERS MARKET FOR DIABETES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
GCC COUNTRIES: BIOMARKERS MARKET FOR DIABETES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
NORTH AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
EUROPE: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
ASIA PACIFIC: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
LATIN AMERICA: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
MIDDLE EAST: BIOMARKERS MARKET FOR OBESITY, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
GCC COUNTRIES: BIOMARKERS MARKET FOR OBESITY, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
EUROPE: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER METABOLIC & ENDOCRINE DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
BIOMARKERS FOR CARDIOVASCULAR DISORDERS
 
 
 
 
 
 
TABLE 437
BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
LATIN AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
MIDDLE EAST: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
GCC COUNTRIES: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
BIOMARKERS FOR RENAL DISORDERS
 
 
 
 
 
 
TABLE 445
BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
NORTH AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
EUROPE: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
ASIA PACIFIC: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
LATIN AMERICA: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
MIDDLE EAST: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
GCC COUNTRIES: BIOMARKERS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
NORTH AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
EUROPE: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
ASIA PACIFIC: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
LATIN AMERICA: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
MIDDLE EAST: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
GCC COUNTRIES: BIOMARKERS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
NORTH AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
EUROPE: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
ASIA PACIFIC: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
LATIN AMERICA: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
MIDDLE EAST: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
GCC COUNTRIES: BIOMARKERS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
NORTH AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
EUROPE: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
LATIN AMERICA: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
MIDDLE EAST: BIOMARKERS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
GCC COUNTRIES: BIOMARKERS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
NORTH AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
NORTH AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
NORTH AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
NORTH AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
NORTH AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
US: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
US: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
US: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
US: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
US: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
US: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
US: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
US: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
US: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
US: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
US: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
US: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
US: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
CANADA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
CANADA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
CANADA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
CANADA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
CANADA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
CANADA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
CANADA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
CANADA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
CANADA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
CANADA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
CANADA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
CANADA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
CANADA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
EUROPE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
GERMANY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
GERMANY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
GERMANY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
GERMANY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
GERMANY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
GERMANY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
GERMANY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
GERMANY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
GERMANY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
GERMANY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
GERMANY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
GERMANY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
UK: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
UK: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
UK: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
UK: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
UK: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
UK: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
UK: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
UK: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
UK: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
UK: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
UK: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
UK: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
UK: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
FRANCE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
FRANCE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
FRANCE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
FRANCE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
FRANCE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
FRANCE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
FRANCE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
FRANCE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
FRANCE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
FRANCE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
FRANCE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
FRANCE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
ITALY: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
ITALY: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
ITALY: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
ITALY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
ITALY: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
ITALY: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
ITALY: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
ITALY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
ITALY: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
ITALY: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
ITALY: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
ITALY: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
ITALY: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
ITALY: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
ITALY: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
SPAIN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
SPAIN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
SPAIN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
SPAIN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
SPAIN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
SPAIN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
SPAIN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
SPAIN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
SPAIN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 613
SPAIN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 614
SPAIN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
SPAIN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
SPAIN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
SPAIN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
SPAIN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
REST OF EUROPE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
REST OF EUROPE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
REST OF EUROPE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 622
REST OF EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 623
REST OF EUROPE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 624
REST OF EUROPE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 625
REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 626
REST OF EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 627
REST OF EUROPE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 628
REST OF EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 629
REST OF EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 630
REST OF EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 631
REST OF EUROPE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 632
REST OF EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 633
REST OF EUROPE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 634
ASIA PACIFIC: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 635
ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 636
ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 637
ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 638
ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 639
ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 640
ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 641
ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 642
ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 643
ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 644
ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 645
ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 646
ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 647
ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 648
ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 649
ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 650
CHINA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 651
CHINA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 652
CHINA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 653
CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 654
CHINA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 655
CHINA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 656
CHINA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 657
CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 658
CHINA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 659
CHINA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 660
CHINA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 661
CHINA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 662
CHINA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 663
CHINA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 664
CHINA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 665
JAPAN: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 666
JAPAN: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 667
JAPAN: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 668
JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 669
JAPAN: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 670
JAPAN: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 671
JAPAN: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 672
JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 673
JAPAN: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 674
JAPAN: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 675
JAPAN: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 676
JAPAN: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 677
JAPAN: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 678
JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 679
JAPAN: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 680
INDIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 681
INDIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 682
INDIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 683
INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 684
INDIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 685
INDIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 686
INDIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 687
INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 688
INDIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 689
INDIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 690
INDIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 691
INDIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 692
INDIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 693
INDIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 694
INDIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 695
SOUTH KOREA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 696
SOUTH KOREA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 697
SOUTH KOREA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 698
SOUTH KOREA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 699
SOUTH KOREA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 700
SOUTH KOREA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 701
SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 702
SOUTH KOREA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 703
SOUTH KOREA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 704
SOUTH KOREA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 705
SOUTH KOREA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 706
SOUTH KOREA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 707
SOUTH KOREA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 708
SOUTH KOREA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 709
SOUTH KOREA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 710
AUSTRALIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 711
AUSTRALIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 712
AUSTRALIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 713
AUSTRALIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 714
AUSTRALIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 715
AUSTRALIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 716
AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 717
AUSTRALIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 718
AUSTRALIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 719
AUSTRALIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 720
AUSTRALIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 721
AUSTRALIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 722
AUSTRALIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 723
AUSTRALIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 724
AUSTRALIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 725
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 726
REST OF ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 727
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 728
REST OF ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 729
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 730
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 731
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 732
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 733
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 734
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 735
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 736
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 737
REST OF ASIA PACIFIC: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 738
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 739
REST OF ASIA PACIFIC: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 740
LATIN AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 741
LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 742
LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 743
LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 744
LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 745
LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 746
LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 747
LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 748
LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 749
LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 750
LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 751
LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 752
LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 753
LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 754
LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 755
LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 756
BRAZIL: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 757
BRAZIL: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 758
BRAZIL: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 759
BRAZIL: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 760
BRAZIL: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 761
BRAZIL: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 762
BRAZIL: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 763
BRAZIL: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 764
BRAZIL: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 765
BRAZIL: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 766
BRAZIL: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 767
BRAZIL: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 768
BRAZIL: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 769
BRAZIL: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 770
BRAZIL: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 771
MEXICO: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 772
MEXICO: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 773
MEXICO: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 774
MEXICO: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 775
MEXICO: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 776
MEXICO: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 777
MEXICO: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 778
MEXICO: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 779
MEXICO: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 780
MEXICO: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 781
MEXICO: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 782
MEXICO: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 783
MEXICO: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 784
MEXICO: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 785
MEXICO: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 786
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 787
REST OF LATIN AMERICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 788
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 789
REST OF LATIN AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 790
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 791
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 792
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 793
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 794
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 795
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 796
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 797
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 798
REST OF LATIN AMERICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 799
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 800
REST OF LATIN AMERICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 801
MIDDLE EAST: BIOMARKERS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 802
MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 803
MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 804
MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 805
MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 806
MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 807
MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 808
MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 809
MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 810
MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 811
MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 812
MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 813
MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 814
MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 815
MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 816
MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 817
GCC COUNTRIES: BIOMARKERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 818
GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 819
GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 820
GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 821
GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 822
GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 823
GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 824
GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 825
GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 826
GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 827
GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 828
GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 829
GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 830
GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 831
GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 832
GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 833
SAUDI ARABIA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 834
SAUDI ARABIA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 835
SAUDI ARABIA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 836
SAUDI ARABIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 837
SAUDI ARABIA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 838
SAUDI ARABIA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 839
SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 840
SAUDI ARABIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 841
SAUDI ARABIA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 842
SAUDI ARABIA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 843
SAUDI ARABIA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 844
SAUDI ARABIA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 845
SAUDI ARABIA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 846
SAUDI ARABIA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 847
SAUDI ARABIA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 848
UAE: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 849
UAE: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 850
UAE: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 851
UAE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 852
UAE: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 853
UAE: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 854
UAE: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 855
UAE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 856
UAE: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 857
UAE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 858
UAE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 859
UAE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 860
UAE: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 861
UAE: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 862
UAE: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 863
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 864
REST OF GCC COUNTRIES: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 865
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 866
REST OF GCC COUNTRIES: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 867
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 868
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 869
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 870
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 871
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 872
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 873
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 874
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 875
REST OF GCC COUNTRIES: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 876
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 877
REST OF GCC COUNTRIES: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 878
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 879
REST OF MIDDLE EAST: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 880
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 881
REST OF MIDDLE EAST: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 882
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 883
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 884
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 885
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 886
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 887
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 888
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 889
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 890
REST OF MIDDLE EAST: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 891
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 892
REST OF MIDDLE EAST: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 893
AFRICA: BIOMARKERS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 894
AFRICA: BIOMARKER CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 895
AFRICA: BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 896
AFRICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 897
AFRICA: BIOMARKERS MARKET, BY RESEARCH AREA, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 898
AFRICA: BIOMARKERS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 899
AFRICA: BIOMARKERS MARKET FOR IMMUNOASSAYS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 900
AFRICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 901
AFRICA: BIOMARKERS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 902
AFRICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 903
AFRICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 904
AFRICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 905
AFRICA: BIOMARKERS MARKET FOR METABOLIC & ENDOCRINE DISORDERS, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 906
AFRICA: BIOMARKERS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 907
AFRICA: BIOMARKERS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 908
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOMARKERS MARKET
 
 
 
 
 
 
TABLE 909
BIOMARKERS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 910
BIOMARKERS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 911
BIOMARKERS MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 912
BIOMARKERS MARKET: TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
TABLE 913
BIOMARKERS MARKET: APPLICATION FOOTPRINT
 
 
 
 
 
 
TABLE 914
BIOMARKERS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
 
 
 
 
 
 
TABLE 915
BIOMARKERS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES PLAYERS
 
 
 
 
 
 
TABLE 916
BIOMARKERS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 917
BIOMARKERS MARKET: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 918
BIOMARKERS MARKET: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 919
F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 920
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 921
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 922
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 923
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 924
DANAHER CORPORATION: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 925
ILLUMINA, INC.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 926
ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 927
ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 928
ILLUMINA, INC.: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 929
MERCK KGAA: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 930
MERCK KGAA: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 931
MERCK KGAA: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 932
MERCK KGAA: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 933
THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 934
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 935
THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 936
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 937
THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 938
QIAGEN: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 939
QIAGEN: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 940
QIAGEN: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 941
QIAGEN: DEALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 942
QIAGEN: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 943
ABBOTT: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 944
ABBOTT: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 945
ABBOTT: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 946
ABBOTT: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 947
AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 948
AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 949
AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 950
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 951
REVVITY INC.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 952
REVVITY INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 953
REVVITY INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 954
CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 955
CHARLES RIVER LABORATORIES: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 956
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 957
BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 958
BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 959
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 960
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 961
EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 962
EUROFINS SCIENTIFIC: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 963
EUROFINS SCIENTIFIC: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 964
BIOMÉRIEUX: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 965
BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 966
BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 967
BIOMÉRIEUX: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 968
BIOMÉRIEUX: EXPANSIONS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 969
JSR CORPORATION: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 970
JSR CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 971
JSR CORPORATION: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 972
GUARDANT HEALTH: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 973
GUARDANT HEALTH: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 974
GUARDANT HEALTH: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026
 
 
 
 
 
 
TABLE 975
GUARDANT HEALTH: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 976
LABCORP: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 977
LABCORP: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 978
LABCORP: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 979
LABCORP: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 980
QUANTERIX: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 981
QUANTERIX: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 982
QUANTERIX: PRODUCT LAUNCHES, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 983
QUANTERIX: DEALS, JANUARY 2023—JUNE 2026
 
 
 
 
 
 
TABLE 984
MESO SCALE DIAGNOSTICS, LLC: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 985
MESO SCALE DIAGNOSTICS, LLC: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 986
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 987
SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
 
 
 
 
 
 
TABLE 988
CELERION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 989
STANDARD BIOTOOLS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 990
SEBIA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 991
BIOAGILYTIX LABS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 992
STRESSMARQ BIOSCIENCES INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 993
NORTHEAST BIOANALYTICAL LABORATORIES LLC: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 994
SIGNOSIS: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 995
SERIMMUNE: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 996
THERAINDX LIFESCIENCES PVT. LTD.: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 997
SYNEXA LIFE SCIENCES BV: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 998
DIATECH PHARMACOGENETICS: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 999
PILLAR BIOSCIENCES: BUSINESS OVERVIEW
 
 
 
 
 
 
TABLE 1000
R-BIOPHARM AG: BUSINESS OVERVIEW
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
BIOMARKERS MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
 
 
FIGURE 2
BIOMARKERS MARKET: YEARS CONSIDERED
 
 
 
 
 
 
FIGURE 3
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 4
GLOBAL BIOMARKERS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF BIOMARKERS MARKET
 
 
 
 
 
 
FIGURE 7
HIGH-GROWTH SEGMENTS IN BIOMARKERS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOMARKERS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 9
RISING ADOPTION OF PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH
 
 
 
 
 
 
FIGURE 10
CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 11
CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 13
BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 14
BIOMARKERS MARKET: PORTERS FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 15
BIOMARKERS MARKET: SUPPLY CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 16
BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 17
BIOMARKERS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 18
AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025 (USD)
 
 
 
 
 
 
FIGURE 19
INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
 
 
 
 
 
 
FIGURE 20
BIOMARKERS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
 
 
 
 
 
 
FIGURE 21
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
 
 
 
 
 
 
FIGURE 22
TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015–2025
 
 
 
 
 
 
FIGURE 23
IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
 
 
 
 
 
 
FIGURE 24
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
 
 
 
 
 
 
FIGURE 25
KEY BUYING CRITERIA, BY END USER
 
 
 
 
 
 
FIGURE 26
NORTH AMERICA: BIOMARKERS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 27
ASIA PACIFIC: BIOMARKERS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 28
REVENUE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET, 2023–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 29
MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOMARKERS MARKET (2025)
 
 
 
 
 
 
FIGURE 30
BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 31
BIOMARKERS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 32
BIOMARKERS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 33
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 34
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 35
BIOMARKERS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
 
 
FIGURE 36
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
MERCK KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
QIAGEN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
ABBOTT: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
REVVITY INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
BIOMÉRIEUX: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 49
JSR CORPORATION: COMPANY SNAPSHOT (2024)
 
 
 
 
 
 
FIGURE 50
GUARDANT HEALTH: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 51
LABCORP: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 52
QUANTERIX: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 53
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT, 2025
 
 
 
 
 
 
FIGURE 54
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 55
BIOMARKERS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
 
 
 
 
 
 
FIGURE 56
BIOMARKERS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
 
 
 
 
 
 
FIGURE 57
MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
 
 
 
 
 
 
FIGURE 58
ILLUSTRATIVE EXAMPLE OF HOFFMANN-LA ROCHE LTD.: REVENUE SHARE ANALYSIS (2025)
 
 
 
 
 
 
FIGURE 59
MARKET SIZE VALIDATION FROM PRIMARY SOURCES
 
 
 
 
 
 
FIGURE 60
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 61
BIOMARKERS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 62
BIOMARKERS MARKET: GROWTH ANALYSIS OF MARKET DYNAMICS
 
 
 
 
 
 
FIGURE 63
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

 

Methodology

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.

The following is a breakdown of the primary respondents:

Biomarkers Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the biomarkers market was generated.
  • The revenues generated from their biomarker products have been determined through annual reports and secondary sources (including paid databases)
  • The products were mapped according to the segments of the market. Percentage shares and splits were determined by each segment's revenue. This was verified using secondary sources and by industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Biomarkers Market : Top-Down and Bottom-Up Approach

Biomarkers Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.

The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.

Key Stakeholders

  • Academic & Research Institutes
  • Biomarkers Assay & Reagent Manufacturers, Vendors, and Distributors
  • Start-ups, platform technology & service providers
  • Contract Research Organizations (CROs)
  • Diagnostic product providing companies
  • Market Research and Consulting Firms
  • Pharmaceutical and Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Forensic Labs
  • Government organizations
  • Private Research Firms
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Hospitals and Diagnostic Laboratories

Report Objectives

  • To define, describe, and forecast the global biomarkers market by offering, type, research area, technology, disease indication, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biomarkers market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To profile the key players in the global biomarkers market and comprehensively analyze their product & service portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
  • To benchmark players within the biomarkers market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product & service strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:

Portfolio Assesment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

Regional Analysis

  • A further breakdown of the Rest of Asia Pacific biomarkers market into countries
  • A further breakdown of the Rest of Europe biomarkers market into countries
  • A further breakdown of the Rest of Latin America biomarkers market into countries

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Biomarkers Market

avtar

Jasper

Jun, 2026

I reviewed the Biomarkers Market report to evaluate segmentation across diagnostic and prognostic applications, and it clarified how strongly clinical validation is shaping commercial adoption decisions..

avtar

Rowan

Jun, 2026

After going through the Biomarkers Market insights, I see clearer investment signals around companion diagnostics and liquid biopsy platforms, especially where recurring revenue models are emerging..

avtar

Elowen

Jun, 2026

From an operational standpoint, the Biomarkers Market analysis helped me understand how variability in assay standardization and regulatory pathways is impacting lab integration timelines..

avtar

Patrick

Mar, 2022

Looking forward to gain more insights on the global Biomarkers Market.

avtar

Raymond

Mar, 2022

What are the growth opportunities in Biomarkers Market?.

avtar

Jack

Mar, 2022

Can you enlighten us on the end users in Biomarkers Market?.

bottom banner
DMCA.com Protection Status
popup img